盐酸莫西沙星的结构分析研究

报道了盐酸莫西沙星的元素分析、红外光谱(IR) 、紫外光谱(UV) 、质谱(MS) 、氢-氢相关谱(1H-1HCOSY) 、碳谱(DEPT-45、DEPT-90、DEPT-135) 、多键碳氢相关谱(HMBC)等波谱数据,并对特征数据进行了化合物的结构解析。对所有的1H-NMR、13C-NMR谱的信号进行了归属。     

铜（Ⅱ)-氟喹诺酮类抗生素螯合物与虎红体系的吸收和共振瑞利散射光谱及其分析应用研究

在pH 4.2~4.8的B-R缓冲介质中,莫西沙星（MXFX)和加替沙星（GTF)等氟喹诺酮类抗生素（FLQs)能与铜（Ⅱ)形成螯合阳离子,进一步与虎红（Tf)阴离子通过静电引力和疏水作用形成FLQs∶Cu（Ⅱ)∶Tf为1∶1∶1的离子缔合物,体系反应导致共振瑞利散射（RRS)显著增强并出现新的RRS光谱。两种药物的反应产物具有相似的光谱特征,最大RRS峰位于373 nm处,并在590 nm处有1个较小的散射峰。在373 nm处一定浓度的抗生素与散射增强（ΔI)成正比,MXFX和GTF的线性范围分别为0.031~7.8 mg/L和0.029~9.0 mg/L。据此建立了测定氟喹诺酮类药物的新方法,方法用于胶囊和人尿液中FLQs的测定并取得满意结果。同时对反应机理及RRS增强原因进行了讨论。     

Drug–drug interactions between moxifloxacin and rifampicin based on pharmacokinetics in vivo in rats

Moxifloxacin and rifampicin are all the first‐line options for the treatment of active tuberculosis, which are often combined for the treatment of multidrug resistance pulmonary tuberculosis in clinic. However, the potential drug–drug interactions between moxifloxacin and rifampicin were unknown. The aim of this study was to investigate the drug–drug interactions between moxifloxacin and rifampicin based on their pharmacokinetics in vivo after oral administration of the single drug and both drugs, and reveal their mutual effects on their pharmacokinetics. Eighteen male Sprague–Dawley rats were randomly assigned to three groups: moxifloxacin group, rifampicin group and moxifloxacin + rifampicin group. Plasma concentrations of moxifloxacin and rifampicin were determined using LC‐MS at the designated time points after drug administration, and the main pharmacokinetic parameters were calculated. In addition, effects of moxifloxacin and rifampicin on their metabolic rate and absorption were investigated using rat liver microsome incubation systems and Caco‐2 cell transwell model. The main pharmacokinetic parameters of moxifloxacin including T_max, C_max, t_1/2 and AUC_(0–t) increased more in the moxifloxacin + rifampicin group than in the moxifloxacin group, but the difference was not significant (p > 0.05). However, the pharmacokinetic parameters of rifampicin, including peak concentration, area under the concentration–time curve, half‐life and the area under the first moment plasma concentration–time curve, increased significantly (p < 0.05) compared with the rifampicin group, and the time to peak concentration decreased significantly (p < 0.05). The mean residence time of rifampicin also increased in moxifloxacin + rifampicin group compared with the rifampicin group, but the difference was not significant (p > 0.05). The rat liver microsome incubation experiment indicated that moxifloxacin could increase the metabolic rate of rifampicin from 23.7 to 38.7 min. However, the Caco‐2 cell transwell experiment showed that moxifloxacin could not affect the absorption rate of rifampicin. These changes could enhance the drug efficacy, but they could also cause drug accumulation, which might induce adverse effect, so it was suggested that the drug dosage should be adjusted and the drug concentration in plasma should be monitored if moxifloxacin and rifampicin are co‐administered. Copyright © 2016 John Wiley & Sons, Ltd.     

荧光光谱法研究拜复乐与小牛胸腺DNA的作用机理

用荧光光谱法研究了拜复乐(MXFX)与小牛胸腺DNA(ctDNA)之间的相互作用。在pH=7.4的TrisHCl缓冲溶液中,MXFX的荧光激发峰和发射峰分别位于291 nm和462 nm。ctDNA的加入对MXFX的荧光有静态猝灭作用,这种荧光静态猝灭作用是由ctDNA和MXFX结合引起的,作用力为氢键或范德华力,结合常数为1.28×105L/mol(25℃)。采用离子强度的影响、碘离子猝灭及溴乙锭竞争作用实验研究了MXFX与ctDNA间的相互作用,结果表明MXFX与DNA的结合是MXFX嵌入到DNA中相邻2个碱基对之间,属于嵌入结合模式。     

氟喹诺酮类抗生素与磷钨酸体系的共振瑞利散射光谱研究及其分析应用

在5.0 mol/L的HCl缓冲介质中,磷钨酸（Pwa）与莫西沙星(MXFX)和加替沙星（GTF）等氟喹诺酮类抗生素(FLQs)相互作用形成摩尔比1∶1离子缔合物,导致体系的共振瑞利散射(RRS)显著增强并出现新的RRS光谱。 MXFX和GTF的反应产物具有相似的光谱特征,最大散射波长位于320 nm附近,且药物浓度与散射增强(ΔI)成正比,2种氟喹诺酮类药物的线性范围分别为0.025~6.0 mg/L（MXFX）和0.023~9.0 mg/L（GTF）。 据此可建立用于测定氟喹诺酮类药物的简捷快速灵敏的新方法,方法用于胶囊和人尿液中的FLQs测定并取得满意结果。 并对反应机理和RRS增强的原因进行了讨论。     

莫西沙星及其杂质的合成研究进展

莫西沙星是第四代喹诺酮类抗菌药物,具有抗菌谱广、抗菌活性强、低毒等特点,因此在临床上得到了广泛的应用。莫西沙星在生产、储存过程中容易产生杂质,为了确保临床用药安全有效,莫西沙星的杂质需要进行控制。本文主要对莫西沙星及其杂质的合成研究进展进行综述。     

Differential pulse polarographic determination of Co(II) using moxifloxacine

The polarographic reduction of Co(II) in the presence of moxifloxacin (1-cyclopropyl-7-[(S,S)-2.8-diazabicyclo[4.3.0]non-8-yl]-6-fluoro-8-methoxy-1.4-dihydro-4-oxo-3-quinolinecarboxylic acid) gives rise to an additional adsorption peak corresponding to the reduction of Co(II)-moxifloxacin complex on the mercury drop electrode at −1.17 V. This new peak is applicable to Co(II) determination with the linearity proportional to the Co(II) concentration in the range of 4.93 × 10⁻⁷−6.90 × 10⁻⁵ M and can be attributed to an adsorption-controlled process with an irreversible reduction. Without using moxifloxacin, the polarographic determination of 2.50 × 10⁻⁶ M Co(II) is impossible under the given conditions due to very poor sensitivity at −1.38 V. The proposed method showed good precision and accuracy with a relative standard deviation of 3.01% and relative error of +6.40% for the determination of 2.50 × 10⁻⁶ M Co(II) next to 5.0 × 10⁻⁶ M of Zn(II), Ni(II), and Cd(II). The accuracy of the method was also checked by the determination of Co(II) spiked with tap water and certified sea water, and the percentage recoveries were 97.5 and 96.7%, respectively (n = 4 at 95% confidence interval). The text was submitted by the authors in English.     

药物莫西沙星对Q235钢在盐酸溶液中的缓蚀作用

为了探寻新的环境友好型缓蚀剂,采用电化学方法、失重法和量子化学计算研究了莫西沙星在1 mol/L HCl溶液中对Q235钢的缓蚀性能和缓蚀机理。结果表明,莫西沙星对Q235钢在盐酸溶液中是一种良好的以抑制阴极为主的混合抑制型缓蚀剂,缓蚀效率随其浓度的增加而增大,但随温度增加而减小,35℃下,在其浓度为200 mg/L时,缓蚀效率达90%;莫西沙星在Q235钢表面的吸附为自发过程,且符合Langmuir和El-Awady等温方程,同时,计算和讨论了相关的热力学和动力学参数。此外,采用量子化学计算对莫西沙星的缓蚀机理进行了进一步的分析,结果发现,莫西沙星的缓蚀作用由物理吸附和化学吸附共同产生。     

盐酸莫西沙星对映体及混合体的核磁共振研究

利用核磁共振波谱¹H、¹³C NMR、DEPT、COSY、HSQC、HMBC、2D NOESY谱及¹⁹F-¹³C的偶合裂分,对盐酸莫西沙星对映体纯品（RR或SS）以及它们的混合体（RR/SS）结构进行分析和研究,详细解析了该分子结构的¹H和¹³C谱图归属,¹⁹F-¹³C间的偶合不仅体现在沙星母核中还表现在盐酸莫西沙星中的五元杂环中,且该五元杂环的⁴J_FC大于盐酸莫西沙星中的六元环上³J_FC和⁴J_FC,该文总结了盐酸莫西沙星对映体的波谱特征,确定混合体与纯品的区别方法.     

Development and validation of a RP-HPLC method for simultaneous quantification of bedaquiline (TMC207), moxifloxacin and pyrazinamide in a pharmaceutical powder formulation for inhalation

A reversed phase high performance liquid chromatography (RP-HPLC) method for the simultaneous quantification of bedaquiline (TMC207), moxifloxacin and pyrazinamide in a pharmaceutical powder formulation for inhalation has been developed and validated. The powder was simply dissolved in methanol and the analytes separated in a run time of 20?min on a Luna C18 (2) (150?×?4.6?mm, 5?µm) column using gradient elution with methanol and triethylamine phosphate buffer (pH 2.5) delivered at 1.2?mL/min. The detection (with retention time) was carried out at 269?nm (2.9?min) for pyrazinamide, 296?nm (7.0?min) for moxifloxacin and 225?nm (16.3?min) for bedaquiline, respectively. The method was linear for all analytes in the concentration range 1-100?µg/mL with correlation coefficients >0.998. Lower limits of quantitation (µg/mL) of bedaquiline, moxifloxacin and pyrazinamide were 0.56, 0.43 and 0.24, respectively. The method was accurate (relative error in the range ?0.2 to 2.2) and precise (%RSD ≤6.2) with recovery in the range 100.0–104.7%. The method was successfully applied to determine the drug content and content uniformity of the three analytes in a spray-dried combination powder formulation for inhalation containing L-leucine.